Long term, open-label safety study of oral almotriptan malate 12.5 mg in the treatment of migraine in adolescents.
Phase of Trial: Phase III
Latest Information Update: 14 Apr 2014
At a glance
- Drugs Almotriptan (Primary)
- Indications Migraine
- Focus Adverse reactions
- Sponsors Janssen Inc
- 30 Mar 2010 Actual patient number (447) added as reported by ClinicalTrials.gov.
- 29 Sep 2008 Actual end date (December 2007) added as reported by CT.gov
- 29 Sep 2008 Status changed from active, no longer recruiting to completed as reported by CT.gov